A Strategy for Discovery and Verification of Candidate Biomarkers in Cerebrospinal Fluid of Preclinical Alzheimer’s Disease
Alzheimer’s disease (AD), a progressive neurodegenerative disease, is characterized by the accumulation of senile plaques, neurofibrillary tangles, and loss of synapses and neurons in the brain. The pathophysiological process of AD begins with a long asymptomatic phase, which provides a potential op...
Main Authors: | Xiaofang Zhong, Jingxin Wang, Cynthia Carlsson, Ozioma Okonkwo, Henrik Zetterberg, Lingjun Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-01-01
|
Series: | Frontiers in Molecular Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fnmol.2018.00483/full |
Similar Items
-
Cerebrospinal fluid proteome evaluation in major depressive disorder by mass spectrometry
by: Avery D. Franzen, et al.
Published: (2020-10-01) -
Neuromodulation via the Cerebrospinal Fluid: Insights from Recent in Vitro Studies
by: Andreas Bjorefeldt, et al.
Published: (2018-02-01) -
The Cerebrospinal Fluid in Multiple Sclerosis
by: Florian Deisenhammer, et al.
Published: (2019-04-01) -
An Integrated Quantitative Proteomics Workflow for Cancer Biomarker Discovery and Validation in Plasma
by: Vipin Kumar, et al.
Published: (2020-09-01) -
Global Quantitative Proteomic Profiling through 18O-labeling in Combination with MS/MS Spectra Analysis
by: White, Carl
Published: (2010)